drugset / Trial / NCT00562731

Open-Label Study of ARD-0403 in Testosterone Deficient Men

NCT00562731 ↗

Phase 3 Terminated 150 enrolled Ardana Bioscience Ltd
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Male hypogonadism, a disorder associated with testosterone deficiency, is frequently seen in clinical practice and has significant effects on patient well-being. The purpose of this study is to investigate the efficacy and safety of ARD-0403 as a testosterone replacement therapy in testosterone deficient men.

Timeline

Start
2007-10
Primary completion
—
Completion
2008-06

Outcome

Outcome not reported

Stopped (Business): “Company strategic decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject ARD-0403 Unknown — Other

Indications